The Changing Epidemiology of Pulmonary Infection in Children and Adolescents with Cystic Fibrosis: an 18-year Experience

Overview

Journal Sci Rep

Specialty Science

Date 2024 Apr 20

PMID 38643191

Authors

Jagdev Singh

Sharon Hunt

Sharon Simonds

Christie Boyton

Anna Middleton

Matthew Elias

Susan Towns

Chetan Pandit

Paul Robinson

Dominic A Fitzgerald

Hiran Selvadurai

Affiliations

Soon will be listed here.

Abstract

The impact of evolving treatment regimens, airway clearance strategies, and antibiotic combinations on the incidence and prevalence of respiratory infection in cystic fibrosis (CF) in children and adolescents remains unclear. The incidence, prevalence, and prescription trends from 2002 to 2019 with 18,339 airway samples were analysed. Staphylococcus aureus [- 3.86% (95% CI - 5.28-2.43)] showed the largest annual decline in incidence, followed by Haemophilus influenzae [- 3.46% (95% CI - 4.95-1.96)] and Pseudomonas aeruginosa [- 2.80%95% CI (- 4.26-1.34)]. Non-tuberculous mycobacteria and Burkholderia cepacia showed a non-significant increase in incidence. A similar pattern of change in prevalence was observed. No change in trend was observed in infants < 2 years of age. The mean age of the first isolation of S. aureus (p < 0.001), P. aeruginosa (p < 0.001), H. influenza (p < 0.001), Serratia marcescens (p = 0.006) and Aspergillus fumigatus (p = 0.02) have increased. Nebulised amikacin (+ 3.09 ± 2.24 prescription/year, p = 0.003) and colistin (+ 1.95 ± 0.3 prescriptions/year, p = 0.032) were increasingly prescribed, while tobramycin (- 8.46 ± 4.7 prescriptions/year, p < 0.001) showed a decrease in prescription. Dornase alfa and hypertonic saline nebulisation prescription increased by 16.74 ± 4.1 prescriptions/year and 24 ± 4.6 prescriptions/year (p < 0.001). There is a shift in CF among respiratory pathogens and prescriptions which reflects the evolution of cystic fibrosis treatment strategies over time.

Citing Articles

Genetic and clinical factors influencing CF-associated liver disease: the impact of variants and genotypes in Romanian pediatric cystic fibrosis patients.

Moiceanu E, Stan I, Mosescu S, Chis A, Vulturar R, Leucuta D Med Pharm Rep. 2024; 97(4):429-437.

PMID: 39502765 PMC: 11534388. DOI: 10.15386/mpr-2801.

The role of NETosis in heart failure.

Kostin S, Krizanic F, Kelesidis T, Pagonas N Heart Fail Rev. 2024; 29(5):1097-1106.

PMID: 39073665 DOI: 10.1007/s10741-024-10421-x.

References

Coburn B, Wang P, Diaz Caballero J, Clark S, Brahma V, Donaldson S . Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015; 5:10241. PMC: 4431465. DOI: 10.1038/srep10241. View

Hilliard T, Sukhani S, Francis J, Madden N, Rosenthal M, Balfour-Lynn I . Bronchoscopy following diagnosis with cystic fibrosis. Arch Dis Child. 2006; 92(10):898-9. PMC: 2083238. DOI: 10.1136/adc.2006.105825. View

Zainal Abidin N, Gardner A, Robinson H, Haq I, Thomas M, Brodlie M . Trends in nontuberculous mycobacteria infection in children and young people with cystic fibrosis. J Cyst Fibros. 2020; 20(5):737-741. PMC: 8490157. DOI: 10.1016/j.jcf.2020.09.007. View

Ramsay K, Sandhu H, Geake J, Ballard E, ORourke P, Wainwright C . The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. J Cyst Fibros. 2016; 16(1):70-77. DOI: 10.1016/j.jcf.2016.07.010. View

Breuer O, Schultz A, Turkovic L, de Klerk N, Keil A, Brennan S . Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2019; 200(5):590-599. DOI: 10.1164/rccm.201810-1919OC. View

Schultz A, Caudri D . Cough swabs less useful but induced sputum very useful in symptomatic older children with cystic fibrosis. Lancet Respir Med. 2018; 6(6):410-411. DOI: 10.1016/S2213-2600(18)30183-8. View

McKay K, Waters D, Gaskin K . The influence of newborn screening for cystic fibrosis on pulmonary outcomes in new South Wales. J Pediatr. 2005; 147(3 Suppl):S47-50. DOI: 10.1016/j.jpeds.2005.08.013. View

Gilligan P . Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991; 4(1):35-51. PMC: 358177. DOI: 10.1128/CMR.4.1.35. View

Govan J, Nelson J . Microbiology of lung infection in cystic fibrosis. Br Med Bull. 1992; 48(4):912-30. DOI: 10.1093/oxfordjournals.bmb.a072585. View

10.

Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson C, Robinson P . Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med. 2011; 184(1):75-81. DOI: 10.1164/rccm.201011-1892OC. View

11.

Millar F, Simmonds N, Hodson M . Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros. 2009; 8(6):386-91. DOI: 10.1016/j.jcf.2009.08.003. View

12.

VanDevanter D, LiPuma J, Konstan M . Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact. J Cyst Fibros. 2023; 23(1):58-64. PMC: 10949087. DOI: 10.1016/j.jcf.2023.09.011. View

13.

Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M . Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis. 2008; 28(2):191-5. DOI: 10.1007/s10096-008-0605-4. View

14.

Flume P, OSullivan B, Robinson K, Goss C, Mogayzel Jr P, Willey-Courand D . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176(10):957-69. DOI: 10.1164/rccm.200705-664OC. View

15.

Lyczak J, Cannon C, Pier G . Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002; 15(2):194-222. PMC: 118069. DOI: 10.1128/CMR.15.2.194-222.2002. View

16.

Elborn J, Hodson M, Bertram C . Implementation of European standards of care for cystic fibrosis--control and treatment of infection. J Cyst Fibros. 2009; 8(3):211-7. DOI: 10.1016/j.jcf.2009.03.001. View

17.

Fischer A, Planet P . A birth cohort approach to understanding cystic fibrosis lung infections. J Cyst Fibros. 2023; 23(1):8-11. DOI: 10.1016/j.jcf.2023.10.014. View

18.

Nichols D, Donaldson S, Frederick C, Freedman S, Gelfond D, Hoffman L . PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros. 2021; 20(2):205-212. PMC: 8686210. DOI: 10.1016/j.jcf.2021.02.003. View

19.

Burns J, Emerson J, Stapp J, Yim D, Krzewinski J, Louden L . Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998; 27(1):158-63. DOI: 10.1086/514631. View

20.

Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L . Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest. 2009; 136(6):1554-1560. DOI: 10.1378/chest.09-0132. View